Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 13 December 1991:
Vol. 254. no. 5038, pp. 1643 - 1647
DOI: 10.1126/science.1840703

Articles

Science, Vol 254, Issue 5038, 1643-1647
Copyright © 1991 by American Association for the Advancement of Science


articles

A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma

P van der Bruggen, C Traversari, P Chomez, C Lurquin, E De Plaen, B Van den Eynde, A Knuth, and T Boon

Ludwig Institute for Cancer Research, Brussels, Belgium.

Many human melanoma tumors express antigens that are recognized in vitro by cytolytic T lymphocytes (CTLs) derived from the tumor-bearing patient. A gene was identified that directed the expression of antigen MZ2-E on a human melanoma cell line. This gene shows no similarity to known sequences and belongs to a family of at least three genes. It is expressed by the original melanoma cells, other melanoma cell lines, and by some tumor cells of other histological types. No expression was observed in a panel of normal tissues. Antigen MZ2-E appears to be presented by HLA-A1; anti-MZ2-E CTLs of the original patient recognized two melanoma cell lines of other HLA-A1 patients that expressed the gene. Thus, precisely targeted immunotherapy directed against antigen MZ2-E could be provided to individuals identified by HLA typing and analysis of the RNA of a small tumor sample.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells.
V. Francois, S. Ottaviani, N. Renkvist, J. Stockis, G. Schuler, K. Thielemans, D. Colau, M. Marchand, T. Boon, S. Lucas, et al. (2009)
Cancer Res. 69, 4335-4345
   Abstract »    Full Text »    PDF »
Homo sapiens Lactate Dehydrogenase c (Ldhc) Gene Expression in Cancer Cells Is Regulated by Transcription Factor Sp1, CREB, and CpG Island Methylation.
H. Tang and E. Goldberg (2009)
J Androl 30, 157-167
   Abstract »    Full Text »    PDF »
Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/- Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN-{alpha}2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.
J. M. Kirkwood, S. Lee, S. J. Moschos, M. R. Albertini, J. C. Michalak, C. Sander, T. Whiteside, L. H. Butterfield, and L. Weiner (2009)
Clin. Cancer Res. 15, 1443-1451
   Abstract »    Full Text »    PDF »
Recent Advances in Cancer Vaccines: An Overview.
K. Itoh, A. Yamada, T. Mine, and M. Noguchi (2009)
Jpn. J. Clin. Oncol. 39, 73-80
   Abstract »    Full Text »    PDF »
B7 Blockade Alters the Balance between Regulatory T Cells and Tumor-reactive T Cells for Immunotherapy of Cancer.
P. Zhou, X. Zheng, H. Zhang, Y. Liu, and P. Zheng (2009)
Clin. Cancer Res. 15, 960-970
   Abstract »    Full Text »    PDF »
CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens.
L. G. Almeida, N. J. Sakabe, A. R. deOliveira, M. C. C. Silva, A. S. Mundstein, T. Cohen, Y.-T. Chen, R. Chua, S. Gurung, S. Gnjatic, et al. (2009)
Nucleic Acids Res. 37, D816-D819
   Abstract »    Full Text »    PDF »
Genome-wide analysis of cancer/testis gene expression.
O. Hofmann, O. L. Caballero, B. J. Stevenson, Y.-T. Chen, T. Cohen, R. Chua, C. A. Maher, S. Panji, U. Schaefer, A. Kruger, et al. (2008)
PNAS 105, 20422-20427
   Abstract »    Full Text »    PDF »
MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency.
Y. Godet, A. Moreau-Aubry, Y. Guilloux, V. Vignard, A. Khammari, B. Dreno, F. Jotereau, and N. Labarriere (2008)
J. Exp. Med. 205, 2673-2682
   Abstract »    Full Text »    PDF »
Identification of a Novel Tumor-Associated Antigen, Cadherin 3/P-Cadherin, as a Possible Target for Immunotherapy of Pancreatic, Gastric, and Colorectal Cancers.
K. Imai, S. Hirata, A. Irie, S. Senju, Y. Ikuta, K. Yokomine, M. Harao, M. Inoue, T. Tsunoda, S. Nakatsuru, et al. (2008)
Clin. Cancer Res. 14, 6487-6495
   Abstract »    Full Text »    PDF »
The Melanoma-Associated Antigen A3 Mediates Fibronectin-Controlled Cancer Progression and Metastasis.
W. Liu, S. Cheng, S. L. Asa, and S. Ezzat (2008)
Cancer Res. 68, 8104-8112
   Abstract »    Full Text »    PDF »
Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non-Small-Cell Lung Cancer.
M. Barve, J. Bender, N. Senzer, C. Cunningham, F. A. Greco, D. McCune, R. Steis, H. Khong, D. Richards, J. Stephenson, et al. (2008)
J. Clin. Oncol. 26, 4418-4425
   Abstract »    Full Text »    PDF »
Implications of Aging and Self-Tolerance on the Generation of Immune and Antitumor Immune Responses.
A. L. Dominguez and J. Lustgarten (2008)
Cancer Res. 68, 5423-5431
   Abstract »    Full Text »    PDF »
Cancer Immunology.
O. J. Finn (2008)
N. Engl. J. Med. 358, 2704-2715
   Full Text »    PDF »
Fibroblast Growth Factor 2 and Estrogen Control the Balance of Histone 3 Modifications Targeting MAGE-A3 in Pituitary Neoplasia.
X. Zhu, S. L. Asa, and S. Ezzat (2008)
Clin. Cancer Res. 14, 1984-1996
   Abstract »    Full Text »    PDF »
The Use of Filamentous Bacteriophage fd to Deliver MAGE-A10 or MAGE-A3 HLA-A2-Restricted Peptides and to Induce Strong Antitumor CTL Responses.
R. Sartorius, P. Pisu, L. D'Apice, L. Pizzella, C. Romano, G. Cortese, A. Giorgini, A. Santoni, F. Velotti, and P. De Berardinis (2008)
J. Immunol. 180, 3719-3728
   Abstract »    Full Text »    PDF »
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.
M. Fasso, R. Waitz, Y. Hou, T. Rim, N. M. Greenberg, N. Shastri, L. Fong, and J. P. Allison (2008)
PNAS 105, 3509-3514
   Abstract »    Full Text »    PDF »
Efficient Identification of a Novel Cancer/Testis Antigen for Immunotherapy Using Three-Step Microarray Analysis.
T. Yokoe, F. Tanaka, K. Mimori, H. Inoue, T. Ohmachi, M. Kusunoki, and M. Mori (2008)
Cancer Res. 68, 1074-1082
   Abstract »    Full Text »    PDF »
An Oncolytic Adenovirus Redirected with a Tumor-Specific T-Cell Receptor.
Z. Sebestyen, J. de Vrij, M. Magnusson, R. Debets, and R. Willemsen (2007)
Cancer Res. 67, 11309-11316
   Abstract »    Full Text »    PDF »
A Mycoplasma Peptide Elicits Heteroclitic CD4+ T Cell Responses against Tumor Antigen MAGE-A6.
L. Vujanovic, M. Mandic, W. C. Olson, J. M. Kirkwood, and W. J. Storkus (2007)
Clin. Cancer Res. 13, 6796-6806
   Abstract »    Full Text »    PDF »
Identification of a Novel Cancer-Testis Antigen CRT2 Frequently Expressed in Various Cancers Using Representational Differential Analysis.
E. Hayashi, Y. Matsuzaki, G. Hasegawa, T. Yaguchi, S. Kurihara, T. Fujita, T. Kageshita, M. Sano, and Y. Kawakami (2007)
Clin. Cancer Res. 13, 6267-6274
   Abstract »    Full Text »    PDF »
The Cancer/Testis Antigen Melanoma-Associated Antigen-A3/A6 Is a Novel Target of Fibroblast Growth Factor Receptor 2-IIIb through Histone H3 Modifications in Thyroid Cancer.
T. Kondo, X. Zhu, S. L. Asa, and S. Ezzat (2007)
Clin. Cancer Res. 13, 4713-4720
   Abstract »    Full Text »    PDF »
Identification and Characterization of ErbB-3-Binding Protein-1 as a Target for Immunotherapy.
S. J. A. M. Santegoets, M. W. J. Schreurs, A. W. Reurs, J. J. Lindenberg, E. W. M. Kueter, A. J. M. van den Eertwegh, E. Hooijberg, R. J. Brandwijk, S. E. Hufton, H. R. Hoogenboom, et al. (2007)
J. Immunol. 179, 2005-2012
   Abstract »    Full Text »    PDF »
Single mage gene in the chicken genome encodes CMage, a protein with functional similarities to mammalian type II Mage proteins.
N. Lopez-Sanchez, Z. Gonzalez-Fernandez, M. Niinobe, K. Yoshikawa, and J. M. Frade (2007)
Physiol Genomics 30, 156-171
   Abstract »    Full Text »    PDF »
Immunologic Approaches to Ovarian Cancer Treatment.
P. Sabbatini and K. Odunsi (2007)
J. Clin. Oncol. 25, 2884-2893
   Abstract »    Full Text »    PDF »
Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia.
K. L. Kislin, M. T. Marron, G. Li, M. W. Graner, and E. Katsanis (2007)
FASEB J 21, 2173-2184
   Abstract »    Full Text »    PDF »
Detection of MAGE-A Transcripts in Bone Marrow Is an Independent Prognostic Factor in Operable Non-Small-Cell Lung Cancer.
W. Sienel, I. Mecklenburg, S. Dango, P. Ehrhardt, A. Kirschbaum, B. Passlick, and K. Pantel (2007)
Clin. Cancer Res. 13, 3840-3847
   Abstract »    Full Text »    PDF »
Comparative Prime-Boost Vaccinations Using Semliki Forest Virus, Adenovirus, and ALVAC Vectors Demonstrate Differences in the Generation of a Protective Central Memory CTL Response against the P815 Tumor.
T. I. Naslund, C. Uyttenhove, E. K. L. Nordstrom, D. Colau, G. Warnier, M. Jondal, B. J. Van den Eynde, and P. Liljestrom (2007)
J. Immunol. 178, 6761-6769
   Abstract »    Full Text »    PDF »
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.
P. Sharma, Y. Shen, S. Wen, S. Yamada, A. A. Jungbluth, S. Gnjatic, D. F. Bajorin, V. E. Reuter, H. Herr, L. J. Old, et al. (2007)
PNAS 104, 3967-3972
   Abstract »    Full Text »    PDF »
Human Tumor Immunology at the Molecular Divide.
O. J. Finn (2007)
J. Immunol. 178, 2615-2616
   Full Text »    PDF »
Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials.
G. Parmiani, A. De Filippo, L. Novellino, and C. Castelli (2007)
J. Immunol. 178, 1975-1979
   Abstract »    Full Text »    PDF »
CABYR Is a Novel Cancer-Testis Antigen in Lung Cancer.
C. Luo, X. Xiao, D. Liu, S. Chen, M. Li, A. Xu, J. Liu, S. Gao, S. Wu, and D. He (2007)
Clin. Cancer Res. 13, 1288-1297
   Abstract »    Full Text »    PDF »
Opa Interacting Protein 5 (OIP5) Is a Novel Cancer-testis Specific Gene in Gastric Cancer.
Y. Nakamura, F. Tanaka, H. Nagahara, K. Ieta, N. Haraguchi, K. Mimori, A. Sasaki, H. Inoue, K. Yanaga, and M. Mori (2007)
Ann. Surg. Oncol. 14, 885-892
   Abstract »    Full Text »    PDF »
Distorted Relation between mRNA Copy Number and Corresponding Major Histocompatibility Complex Ligand Density on the Cell Surface.
A. O. Weinzierl, C. Lemmel, O. Schoor, M. Muller, T. Kruger, D. Wernet, J. Hennenlotter, A. Stenzl, K. Klingel, H.-G. Rammensee, et al. (2007)
Mol. Cell. Proteomics 6, 102-113
   Abstract »    Full Text »    PDF »
Active Antiviral T-Lymphocyte Response Can Be Redirected against Tumor Cells by Antitumor Antibody x MHC/Viral Peptide Conjugates.
V. Cesson, K. Stirnemann, B. Robert, I. Luescher, T. Filleron, G. Corradin, J.-P. Mach, and A. Donda (2006)
Clin. Cancer Res. 12, 7422-7430
   Abstract »    Full Text »    PDF »
Immunotherapy for Renal Cell Cancer.
J. C. Yang and R. Childs (2006)
J. Clin. Oncol. 24, 5576-5583
   Abstract »    Full Text »    PDF »
Spontaneous CD8 T Cell Responses against the Melanocyte Differentiation Antigen RAB38/NY-MEL-1 in Melanoma Patients.
S. M. Walton, M. Gerlinger, O. de la Rosa, N. Nuber, A. Knights, A. Gati, M. Laumer, L. Strauss, C. Exner, N. Schafer, et al. (2006)
J. Immunol. 177, 8212-8218
   Abstract »    Full Text »    PDF »
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome..
J. Galon, A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pages, M. Tosolini, M. Camus, A. Berger, P. Wind, et al. (2006)
Science 313, 1960-1964
   Abstract »    Full Text »    PDF »
Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma..
P. Sharma, Y. Shen, S. Wen, D. F. Bajorin, V. E. Reuter, L. J. Old, and A. A. Jungbluth (2006)
Clin. Cancer Res. 12, 5442-5447
   Abstract »    Full Text »    PDF »
Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell-Mediated Patient-Specific Immunotherapy.
M. Sensi and A. Anichini (2006)
Clin. Cancer Res. 12, 5023-5032
   Abstract »    Full Text »    PDF »
MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents.
M. Monte, M. Simonatto, L. Y. Peche, D. R. Bublik, S. Gobessi, M. A. Pierotti, M. Rodolfo, and C. Schneider (2006)
PNAS 103, 11160-11165
   Abstract »    Full Text »    PDF »
Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer..
D. Nagorsen and E. Thiel (2006)
Clin. Cancer Res. 12, 3064-3069
   Abstract »    Full Text »    PDF »
Melanoma Antigen A4 Is Expressed in Non-Small Cell Lung Cancers and Promotes Apoptosis..
T. Peikert, U. Specks, C. Farver, S. C. Erzurum, and S. A.A. Comhair (2006)
Cancer Res. 66, 4693-4700
   Abstract »    Full Text »    PDF »
Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity..
A. D. Cohen, A. Diab, M.-A. Perales, J. D. Wolchok, G. Rizzuto, T. Merghoub, D. Huggins, C. Liu, M. J. Turk, N. P. Restifo, et al. (2006)
Cancer Res. 66, 4904-4912
   Abstract »    Full Text »    PDF »
Identification of a New Cancer/Germline Gene, KK-LC-1, Encoding an Antigen Recognized by Autologous CTL Induced on Human Lung Adenocarcinoma..
T. Fukuyama, T. Hanagiri, M. Takenoyama, Y. Ichiki, M. Mizukami, T. So, M. Sugaya, T. So, K. Sugio, and K. Yasumoto (2006)
Cancer Res. 66, 4922-4928
   Abstract »    Full Text »    PDF »
Promoter Demethylation and Histone Acetylation Mediate Gene Expression of MAGE-A1, -A2, -A3, and -A12 in Human Cancer Cells.
F. Wischnewski, K. Pantel, and H. Schwarzenbach (2006)
Mol. Cancer Res. 4, 339-349
   Abstract »    Full Text »    PDF »
Transient Down-regulation of DNMT1 Methyltransferase Leads to Activation and Stable Hypomethylation of MAGE-A1 in Melanoma Cells.
A. Loriot, E. De Plaen, T. Boon, and C. De Smet (2006)
J. Biol. Chem. 281, 10118-10126
   Abstract »    Full Text »    PDF »
An Inducible Mouse Model of Melanoma Expressing a Defined Tumor Antigen..
I. J. Huijbers, P. Krimpenfort, P. Chomez, M. A. van der Valk, J.-Y. Song, E.-M. Inderberg-Suso, A.-M. Schmitt-Verhulst, A. Berns, and B. J. Van den Eynde (2006)
Cancer Res. 66, 3278-3286
   Abstract »    Full Text »    PDF »
Identification of Oncofetal Antigen/Immature Laminin Receptor Protein Epitopes That Activate BALB/c Mouse OFA/iLRP-Specific Effector and Regulatory T Cell Clones..
J. W. Rohrer, A. L. Barsoum, and J. H. Coggin Jr. (2006)
J. Immunol. 176, 2844-2856
   Abstract »    Full Text »    PDF »
Well-Defined Melanoma Antigens as Progression Markers for Melanoma: Insights into Differential Expression and Host Response Based on Stage.
F. S. Hodi (2006)
Clin. Cancer Res. 12, 673-678
   Full Text »    PDF »
Expression of Synovial Sarcoma X (SSX) Antigens in Epithelial Ovarian Cancer and Identification of SSX-4 Epitopes Recognized by CD4+ T Cells.
D. Valmori, F. Qian, M. Ayyoub, C. Renner, A. Merlo, S. Gjnatic, E. Stockert, D. Driscoll, S. Lele, L. J. Old, et al. (2006)
Clin. Cancer Res. 12, 398-404
   Abstract »    Full Text »    PDF »
A Novel Strategy for the Discovery of MHC Class II-Restricted Tumor Antigens: Identification of a Melanotransferrin Helper T-Cell Epitope.
T. A. Rohn, A. Reitz, A. Paschen, X. D. Nguyen, D. Schadendorf, A. B. Vogt, and H. Kropshofer (2005)
Cancer Res. 65, 10068-10078
   Abstract »    Full Text »    PDF »
Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells.
F. Neumann, C. Wagner, K.-D. Preuss, B. Kubuschok, C. Schormann, S. Stevanovic, and M. Pfreundschuh (2005)
Blood 106, 3105-3113
   Abstract »    Full Text »    PDF »
Turning On/Off Tumor-Specific CTL Response during Progressive Tumor Growth.
Y. Huang, N. Obholzer, R. Fayad, and L. Qiao (2005)
J. Immunol. 175, 3110-3116
   Abstract »    Full Text »    PDF »
Immunogenic Targets in Non-Small Cell Lung Cancer: More Is More.
S. Gnjatic (2005)
Clin. Cancer Res. 11, 5331-5332
   Full Text »    PDF »
Getting to the Surface: A Link Between Tumor Antigen Discovery and Natural Presentation of Peptide-MHC Complexes.
C. E. Clark and R. H. Vonderheide (2005)
Clin. Cancer Res. 11, 5333-5336
   Full Text »    PDF »
Haplotype Loss of HLA Class I Antigen as an Escape Mechanism from Immune Attack in Lung Cancer.
T. So, M. Takenoyama, M. Mizukami, Y. Ichiki, M. Sugaya, T. Hanagiri, K. Sugio, and K. Yasumoto (2005)
Cancer Res. 65, 5945-5952
   Abstract »    Full Text »    PDF »
T Cell Retargeting with MHC Class I-Restricted Antibodies: The CD28 Costimulatory Domain Enhances Antigen-Specific Cytotoxicity and Cytokine Production.
R. A. Willemsen, C. Ronteltap, P. Chames, R. Debets, and R. L. H. Bolhuis (2005)
J. Immunol. 174, 7853-7858
   Abstract »    Full Text »    PDF »
Rationale for Antiangiogenic Cancer Therapy with Vaccination Using Epitope Peptides Derived from Human Vascular Endothelial Growth Factor Receptor 2.
S. Wada, T. Tsunoda, T. Baba, F. J. Primus, H. Kuwano, M. Shibuya, and H. Tahara (2005)
Cancer Res. 65, 4939-4946
   Abstract »    Full Text »    PDF »
Frequent Immune Responses to a Cancer/Testis Antigen, CAGE, in Patients with Microsatellite instability-Positive Endometrial Cancer.
T. Iwata, T. Fujita, N. Hirao, Y. Matsuzaki, T. Okada, H. Mochimaru, N. Susumu, E. Matsumoto, K. Sugano, N. Yamashita, et al. (2005)
Clin. Cancer Res. 11, 3949-3957
   Abstract »    Full Text »    PDF »
Quantification of SSX mRNA Expression in Human Bone and Soft Tissue Tumors Using Nucleic Acid Sequence-Based Amplification.
N. Naka, S. Joyama, Y. Tsukamoto, K. Yoshioka, N. Hashimoto, T. Ujiiye, T. Hayashi, M. Kawase, M. Mano, S. Ishiguro, et al. (2005)
J. Mol. Diagn. 7, 187-197
   Abstract »    Full Text »    PDF »
Cancer/Testis Antigen Expression in Human Mesenchymal Stem Cells: Down-regulation of SSX Impairs Cell Migration and Matrix Metalloproteinase 2 Expression.
G. Cronwright, K. Le Blanc, C. Gotherstrom, P. Darcy, M. Ehnman, and B. Brodin (2005)
Cancer Res. 65, 2207-2215
   Abstract »    Full Text »    PDF »
Expression Profile of Cancer-Testis Genes in 121 Human Colorectal Cancer Tissue and Adjacent Normal Tissue.
M. Li, Y.-H. Yuan, Y. Han, Y.-X. Liu, L. Yan, Y. Wang, and J. Gu (2005)
Clin. Cancer Res. 11, 1809-1814
   Abstract »    Full Text »    PDF »
A Major Histocompatibility Complex{middle dot}Peptide-restricted Antibody and T Cell Receptor Molecules Recognize Their Target by Distinct Binding Modes: CRYSTAL STRUCTURE OF HUMAN LEUKOCYTE ANTIGEN (HLA)-A1{middle dot}MAGE-A1 IN COMPLEX WITH FAB-HYB3.
M. Hulsmeyer, P. Chames, R. C. Hillig, R. L. Stanfield, G. Held, P. G. Coulie, C. Alings, G. Wille, W. Saenger, B. Uchanska-Ziegler, et al. (2005)
J. Biol. Chem. 280, 2972-2980
   Abstract »    Full Text »    PDF »
Uveal and Cutaneous Melanoma: Shared Expression Characteristics of Melanoma-Associated Antigens.
L. C. van Dinten, N. Pul, A. F. van Nieuwpoort, C. J. Out, M. J. Jager, and P. J. van den Elsen (2005)
Invest. Ophthalmol. Vis. Sci. 46, 24-30
   Abstract »    Full Text »    PDF »
Ring Finger Protein 43 as a New Target for Cancer Immunotherapy.
N. Uchida, T. Tsunoda, S. Wada, Y. Furukawa, Y. Nakamura, and H. Tahara (2004)
Clin. Cancer Res. 10, 8577-8586
   Abstract »    Full Text »    PDF »
Mouse Homologue of a Novel Human Oncofetal Antigen, Glypican-3, Evokes T-Cell-Mediated Tumor Rejection without Autoimmune Reactions in Mice.
T. Nakatsura, H. Komori, T. Kubo, Y. Yoshitake, S. Senju, T. Katagiri, Y. Furukawa, M. Ogawa, Y. Nakamura, and Y. Nishimura (2004)
Clin. Cancer Res. 10, 8630-8640
   Abstract »    Full Text »    PDF »
Liposome-Encapsulated CpG Oligodeoxynucleotides as a Potent Adjuvant for Inducing Type 1 Innate Immunity.
Y. Suzuki, D. Wakita, K. Chamoto, Y. Narita, T. Tsuji, T. Takeshima, H. Gyobu, Y. Kawarada, S. Kondo, S. Akira, et al. (2004)
Cancer Res. 64, 8754-8760
   Abstract »    Full Text »    PDF »
The intensity of neutrophil infiltration controls the number of antigen-primed CD8 T cells recruited into cutaneous antigen challenge sites.
T. Engeman, A. V. Gorbachev, D. D. Kish, and R. L. Fairchild (2004)
J. Leukoc. Biol. 76, 941-949
   Abstract »    Full Text »    PDF »
Expression of Cancer-Testis Antigen (CTA) Genes in Intrahepatic Cholangiocarcinoma.
T. Utsunomiya, H. Inoue, F. Tanaka, H. Yamaguchi, M. Ohta, M. Okamoto, K. Mimori, and M. Mori (2004)
Ann. Surg. Oncol. 11, 934-940
   Abstract »    Full Text »    PDF »
Response of Established Human Breast Tumors to Vaccination with Mammaglobin-A cDNA.
K. Narayanan, A. Jaramillo, N. D. Benshoff, L. G. Campbell, T. P. Fleming, J. R. Dietz, and T. Mohanakumar (2004)
J Natl Cancer Inst 96, 1388-1396
   Abstract »    Full Text »    PDF »
Identification of a Novel Human Cancer/Testis Antigen, KM-HN-1, Recognized by Cellular and Humoral Immune Responses.
M. Monji, T. Nakatsura, S. Senju, Y. Yoshitake, M. Sawatsubashi, M. Shinohara, T. Kageshita, T. Ono, A. Inokuchi, and Y. Nishimura (2004)
Clin. Cancer Res. 10, 6047-6057
   Abstract »    Full Text »    PDF »
Melanoma-Associated Antigens in Esophageal Adenocarcinoma: Identification of Novel MAGE-A10 Splice Variants.
J. Lin, L. Lin, D. G. Thomas, J. K. Greenson, T. J. Giordano, G. S. Robinson, R. A. Barve, F. A. Weishaar, J. M. G. Taylor, M. B. Orringer, et al. (2004)
Clin. Cancer Res. 10, 5708-5716
   Abstract »    Full Text »    PDF »
MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription.
S. Laduron, R. Deplus, S. Zhou, O. Kholmanskikh, D. Godelaine, C. De Smet, S. D. Hayward, F. Fuks, T. Boon, and E. De Plaen (2004)
Nucleic Acids Res. 32, 4340-4350
   Abstract »    Full Text »    PDF »
HER-2, gp100, and MAGE-1 Are Expressed in Human Glioblastoma and Recognized by Cytotoxic T Cells.
G. Liu, H. Ying, G. Zeng, C. J. Wheeler, K. L. Black, and J. S. Yu (2004)
Cancer Res. 64, 4980-4986
   Abstract »    Full Text »    PDF »
DNA Array-Based Gene Profiling in Tumor Immunology.
S. Mocellin, E. Wang, M. Panelli, P. Pilati, and F. M. Marincola (2004)
Clin. Cancer Res. 10, 4597-4606
   Abstract »    Full Text »    PDF »
Intratumoral CD8+ T Lymphocytes as a Prognostic Factor of Survival in Endometrial Carcinoma.
S. Kondratiev, E. Sabo, E. Yakirevich, O. Lavie, and M. B. Resnick (2004)
Clin. Cancer Res. 10, 4450-4456
   Abstract »    Full Text »    PDF »
Simultaneous Cellular and Humoral Immune Response against Mutated p53 in a Patient with Lung Cancer.
Y. Ichiki, M. Takenoyama, M. Mizukami, T. So, M. Sugaya, M. Yasuda, T. So, T. Hanagiri, K. Sugio, and K. Yasumoto (2004)
J. Immunol. 172, 4844-4850
   Abstract »    Full Text »    PDF »
A Cleaved Form of MAGE-A4 Binds to Miz-1 and Induces Apoptosis in Human Cells.
T. Sakurai, K. Itoh, H. Higashitsuji, T. Nagao, K. Nonoguchi, T. Chiba, and J. Fujita (2004)
J. Biol. Chem. 279, 15505-15514
   Abstract »    Full Text »    PDF »
Treatment of Melanoma with 5-Fluorouracil or Dacarbazine In Vitro Sensitizes Cells to Antigen-Specific CTL Lysis through Perforin/Granzyme- and Fas-Mediated Pathways.
S. Yang and F. G. Haluska (2004)
J. Immunol. 172, 4599-4608
   Abstract »    Full Text »    PDF »
NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors.
Y. Sugita, H. Wada, S. Fujita, T. Nakata, S. Sato, Y. Noguchi, A. A. Jungbluth, M. Yamaguchi, Y.-T. Chen, E. Stockert, et al. (2004)
Cancer Res. 64, 2199-2204
   Abstract »    Full Text »    PDF »
DAMAGE, a Novel {alpha}-Dystrobrevin-associated MAGE Protein in Dystrophin Complexes.
D. E. Albrecht and S. C. Froehner (2004)
J. Biol. Chem. 279, 7014-7023
   Abstract »    Full Text »    PDF »
Generation and Targeting of Human Tumor-Specific Tc1 and Th1 Cells Transduced with a Lentivirus Containing a Chimeric Immunoglobulin T-Cell Receptor.
H. Gyobu, T. Tsuji, Y. Suzuki, T. Ohkuri, K. Chamoto, M. Kuroki, H. Miyoshi, Y. Kawarada, H. Katoh, T. Takeshima, et al. (2004)
Cancer Res. 64, 1490-1495
   Abstract »    Full Text »    PDF »
CD4+ T Cells Regulate CD8+ T Cell-Mediated Cutaneous Immune Responses by Restricting Effector T Cell Development through a Fas Ligand-Dependent Mechanism.
A. V. Gorbachev and R. L. Fairchild (2004)
J. Immunol. 172, 2286-2295
   Abstract »    Full Text »    PDF »
Identification of HLA-A24-Restricted CTL Epitope from Cancer-Testis Antigen, NY-ESO-1, and Induction of a Specific Antitumor Immune Response.
H. Yamaguchi, F. Tanaka, M. Ohta, H. Inoue, and M. Mori (2004)
Clin. Cancer Res. 10, 890-896
   Abstract »    Full Text »    PDF »
Humoral Responses to Peptides Correlate with Overall Survival in Advanced Cancer Patients Vaccinated with Peptides Based on Pre-existing, Peptide-Specific Cellular Responses.
T. Mine, Y. Sato, M. Noguchi, T. Sasatomi, R. Gouhara, N. Tsuda, S. Tanaka, H. Shomura, K. Katagiri, T. Rikimaru, et al. (2004)
Clin. Cancer Res. 10, 929-937
   Abstract »    Full Text »    PDF »
Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens.
R. Bellucci, C. J. Wu, S. Chiaretti, E. Weller, F. E. Davies, E. P. Alyea, G. Dranoff, K. C. Anderson, N. C. Munshi, and J. Ritz (2004)
Blood 103, 656-663
   Abstract »    Full Text »    PDF »
Limited Gene Activation in Tumor and Normal Epithelial Cells Treated with the DNA Methyltransferase Inhibitor 5-Aza-2'-deoxycytidine.
A. R. Karpf, A. W. Lasek, T. O. Ririe, A. N. Hanks, D. Grossman, and D. A. Jones (2004)
Mol. Pharmacol. 65, 18-27
   Abstract »    Full Text »    PDF »
Phase I Trial of Large Multivalent Immunogen Derived from Melanoma Lysates in Patients with Disseminated Melanoma.
M. S. Mitchell, J. Kan-Mitchell, P. R. Morrow, D. Darrah, V. E. Jones, and M. F. Mescher (2004)
Clin. Cancer Res. 10, 76-83
   Abstract »    Full Text »    PDF »
Expression of the MAGE-A4 and NY-ESO-1 Cancer-Testis Antigens in Serous Ovarian Neoplasms.
E. Yakirevich, E. Sabo, O. Lavie, S. Mazareb, G. C. Spagnoli, and M. B. Resnick (2003)
Clin. Cancer Res. 9, 6453-6460
   Abstract »    Full Text »    PDF »
Proteasomal targeting of a viral oncogene abrogates oncogenic phenotype and enhances immunogenicity.
J. Tellam, G. Connolly, N. Webb, J. Duraiswamy, and R. Khanna (2003)
Blood 102, 4535-4540
   Abstract »    Full Text »    PDF »
Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus.
V. Karanikas, C. Lurquin, D. Colau, N. van Baren, C. De Smet, B. Lethe, T. Connerotte, V. Corbiere, M.-A. Demoitie, D. Lienard, et al. (2003)
J. Immunol. 171, 4898-4904
   Abstract »    Full Text »    PDF »
Natural T Cell Immunity against Cancer.
D. Nagorsen, C. Scheibenbogen, F. M. Marincola, A. Letsch, and U. Keilholz (2003)
Clin. Cancer Res. 9, 4296-4303
   Abstract »    Full Text »    PDF »
Cooperative Effect between Immunotherapy and Antiangiogenic Therapy Leads to Effective Tumor Rejection in Tolerant Her-2/neu Mice.
C. Cuadros, A. L. Dominguez, G. I. Frost, P. Borgstrom, and J. Lustgarten (2003)
Cancer Res. 63, 5895-5901
   Abstract »    Full Text »    PDF »
NY-ESO-1 and LAGE-1 Cancer-Testis Antigens Are Potential Targets for Immunotherapy in Epithelial Ovarian Cancer.
K. Odunsi, A. A. Jungbluth, E. Stockert, F. Qian, S. Gnjatic, J. Tammela, M. Intengan, A. Beck, B. Keitz, D. Santiago, et al. (2003)
Cancer Res. 63, 6076-6083
   Abstract »    Full Text »    PDF »
The Receptor Tyrosine Kinase Ror2 Associates with the Melanoma-associated Antigen (MAGE) Family Protein Dlxin-1 and Regulates Its Intracellular Distribution.
T. Matsuda, H. Suzuki, I. Oishi, S. Kani, Y. Kuroda, T. Komori, A. Sasaki, K. Watanabe, and Y. Minami (2003)
J. Biol. Chem. 278, 29057-29064
   Abstract »    Full Text »    PDF »
Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy.
K. Matsui, L. A. O'Mara, and P. M. Allen (2003)
Int. Immunol. 15, 797-805
   Abstract »    Full Text »    PDF »



To Advertise     Find Products


Science. ISSN 0036-8075 (print), 1095-9203 (online)